Julia Foldi News Today

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.

Among younger women with breast cancer, it may be possible for many to have a baby after their diagnosis, new research suggests.

UPMC and University of Pittsburgh researchers will test a vaccine to prevent breast cancer in what they say is a revolutionary step in the fight against the most common cancer in women. The seed money — $100,000 — to launch the clinical trial came from the Wexford-based nonprofit, Glimmer of

Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients.

In a trial of durvalumab plus neoadjuvant chemotherapy, efficacy outcomes were similar for African-American (AA) and non-AA patients.

In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients.

FRIDAY, Aug. 19, 2022 (HealthDay News) -- Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients, according to a study published online July 29 in Clinical Cancer Research. Julia Foldi, M.D.,

Findings from a new study led by Yale Cancer Center show the small molecule inhibitor drug, PF05175157, originally developed to treat diabetes by Pfizer, may help in the treatment of breast cancer.